PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24551095-2 2014 Recently, we showed therapeutic effects of the combination of lisinopril (L), an angiotensin converting enzyme (ACE) inhibitor, and spironolactone (S), an aldosterone antagonist, in mice lacking dystrophin and haploinsufficient for utrophin (utrn(+/-);mdx, het mice); both cardiac and skeletal muscle function and histology were improved when these mice were treated early with LS. Lisinopril 62-72 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 81-110 24551095-2 2014 Recently, we showed therapeutic effects of the combination of lisinopril (L), an angiotensin converting enzyme (ACE) inhibitor, and spironolactone (S), an aldosterone antagonist, in mice lacking dystrophin and haploinsufficient for utrophin (utrn(+/-);mdx, het mice); both cardiac and skeletal muscle function and histology were improved when these mice were treated early with LS. Lisinopril 62-72 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 112-115 21422380-5 2011 These effects could be blocked by the ACE inhibitor, lisinopril. Lisinopril 53-63 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 38-41 2155615-1 1990 Two biotinylated derivatives of the angiotensin-converting enzyme (ACE) inhibitor, lisinopril, were synthesized. Lisinopril 83-93 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 67-70 9766448-0 1998 Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo. Lisinopril 0-10 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 15-46 9766448-5 1998 In the present paper, we report on the in vivo effect of lisinopril, an ACE inhibitor, on the proliferative status of murine hematopoietic stem cells triggered into S-phase by irradiation. Lisinopril 57-67 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 72-75 9766448-6 1998 Administration of lisinopril (10 mg/kg) 1 hour after irradiation led to a 90 to 100% inhibition of murine plasma ACE activity as observed during the first 4 hours postirradiation. Lisinopril 18-28 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 113-116 20180641-5 2010 Lisinopril, an ACE inhibitor, is less hypotensive for transgenic mice than for control animals. Lisinopril 0-10 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 15-18 2155615-6 1990 These results indicate that the bound determinant of lisinopril must lie at least 11 A below the outer surface of the ACE molecule. Lisinopril 53-63 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 118-121 31794021-10 2020 Beneficial ACE10 phenotype was reversed by the angiotensin-converting enzyme inhibitor (lisinopril) and thus was dependent on angiotensin-converting enzyme catalytic activity. Lisinopril 88-98 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 47-76 2835538-3 1988 Enzymatically active ACE was isolated from renal homogenates by chromatography using an affinity column constructed by linking an ACE inhibitor, lisinopril, to Affi-Gel 15. Lisinopril 145-155 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 21-24 2835538-3 1988 Enzymatically active ACE was isolated from renal homogenates by chromatography using an affinity column constructed by linking an ACE inhibitor, lisinopril, to Affi-Gel 15. Lisinopril 145-155 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 130-133 34304582-3 2021 Here, we aimed to determine whether lisinopril-tryptophan (lisW-S), a C-domain specific ACE inhibitor that preserves the N-domain catalytic activity, together with sacubitril (NEP inhibitor), differentially influences cardiovascular function and vascular permeability in hypertension compared with omapatrilat and lisinopril+sacubitril which inhibits both the ACE C- and N-domains. Lisinopril 36-46 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 88-91 34304582-3 2021 Here, we aimed to determine whether lisinopril-tryptophan (lisW-S), a C-domain specific ACE inhibitor that preserves the N-domain catalytic activity, together with sacubitril (NEP inhibitor), differentially influences cardiovascular function and vascular permeability in hypertension compared with omapatrilat and lisinopril+sacubitril which inhibits both the ACE C- and N-domains. Lisinopril 36-46 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 360-363 31794021-10 2020 Beneficial ACE10 phenotype was reversed by the angiotensin-converting enzyme inhibitor (lisinopril) and thus was dependent on angiotensin-converting enzyme catalytic activity. Lisinopril 88-98 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 126-155 27992423-8 2016 Further studies in melanoma cells (TM-5) showed that Ang-II induced cell proliferation through ACE activation, an event that could be inhibited either by ACE inhibitor (Lisinopril) or by the silencing of ACE. Lisinopril 169-179 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 154-157 27992423-8 2016 Further studies in melanoma cells (TM-5) showed that Ang-II induced cell proliferation through ACE activation, an event that could be inhibited either by ACE inhibitor (Lisinopril) or by the silencing of ACE. Lisinopril 169-179 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 95-98 27992423-8 2016 Further studies in melanoma cells (TM-5) showed that Ang-II induced cell proliferation through ACE activation, an event that could be inhibited either by ACE inhibitor (Lisinopril) or by the silencing of ACE. Lisinopril 169-179 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 154-157 31307778-5 2019 BTBR ob/ob mice received vehicle, cAng-(1-7), or the ACE inhibitor lisinopril. Lisinopril 67-77 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 53-56 27928554-7 2016 Further, Bleo inducetion of both AGT protein and of caspase-9 were prevented by the ACE inhibitor lisinopril. Lisinopril 98-108 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 84-87